Journal Article

DKFZ-2026-00463

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Illini, O. ; Hund, A.-C. ; Kopp, H.-G. ; Moskovitz, M. ; Mountzios, G. ; Brueckl, W. M. ; Früh, M. ; Leßmann, M.-E. ; Christopoulos, P.DKFZ* ; Stenzinger, A.DKFZ* ; Thomas, M. ; Gillis, R. ; Peled, N. ; Acker, F. ; Addeo, A. ; Charpidou, A. ; Grohé, C. ; Mauti, L. ; Rothschild, S. I. ; Schmid, S. ; Schumann, C. ; Urban, D. ; Wurm, R. ; Ekman, S. ; Skribek, M. ; Glanemann, F. ; Wiesweg, M. ; Ackermann, C. J. ; Agelaki, S. ; Hoffknecht, P. ; Jakopović, M. ; Kern, J. ; König, D. ; Kostenzer, K. ; Kropf-Sanchen, C. ; Laack, E. ; Lang, D. ; Nagl, L. ; Pall, G. ; Reck, M. ; Kian, W. ; Allemann, A. T. ; Alt, J. ; Araújo, D. ; Bokas, A. ; Hannah, F. ; Julie, K.-J. ; Weinlinger, C. ; de Langen, A. J. ; Fergadis, E. G. ; Fountzilas, E. ; Froesch, P. ; Frost, N. ; Griesinger, F. ; Jordan, F. ; Karanikiotis, C. ; Kiesewetter, B. ; Korantzis, I. ; Machado, A. L. ; Economopoulou, P. ; Pilz, A. ; Reimann, P. ; Rittmeyer, A. ; Saad, A. ; Samitas, K. ; Schulmann, K. ; Shah, R. ; Stratmann, J. A. ; Taghizadeh, H. ; Tammoscheit, K. ; Tufman, A. ; Weber, J.-P. ; Wöll, E. ; Valipour, A. ; Overbeck, T. R. ; Hochmair, M. J.

2026
Elsevier Amsterdam

Abstract: HER2 mutations define a distinct, therapeutically actionable subset of non-small cell lung cancer (NSCLC). Trastuzumab deruxtecan (T-DXd) has demonstrated strong activity in clinical trials, but real-world data are limited.We conducted a retrospective, multinational cohort study of patients with advanced HER2-mutant NSCLC treated with T-DXd outside clinical trials between August 2021 and January 2025 across 68 centers in Europe and Israel. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), intracranial efficacy, and safety.Among 168 patients (median age 62 years; 59% female; 56% never-smokers), the ORR was 54.8% (95%CI, 46.9-62.4) and disease control rate 88.7% (95%CI, 82.9-93.1). Median PFS was 7.2 months (95%CI, 6.2-9.7) and OS 18.3 months (95%CI, 13.3-24.8). Treatment-naïve patients (n=18) achieved an ORR of 72.2% (95%CI, 46.5-90.3) and median OS of 22.1 months (95%CI, 10.0-NE). Patients with measurable brain metastases (n=27) had an intracranial ORR of 74.1% (95%CI, 53.7-88.9), including 25.9% complete responses. Grade ≥3 treatment-related adverse events occurred in 32% of patients. Interstitial lung disease (ILD)/pneumonitis occurred in 14% (four fatal cases) of patients, without consistent predictors.In the largest real-world cohort reported to date, T-DXd demonstrated robust systemic and intracranial activity in HER2-mutant NSCLC, including treatment-naïve patients and those with active brain metastases who were largely excluded from prior studies. Toxicity was consistent with previous reports, with ILD remaining the main safety concern. These findings support integration of HER2-targeted therapies into evolving treatment algorithms.

Keyword(s): ErbB2 ; HER2 ; HER2-mutant NSCLC ; Non-small cell lung cancer ; antibody-drug conjugate ; brain metastases ; targeted therapies ; trastuzumab deruxtecan

Note: #NCTZFB9# / #DKTKZFB9# / epub

---

Contributing Institute(s):

1. B063 Krebsgenomforschung (B063)
2. Koordinierungsstelle NCT Heidelberg (HD02)
3. DKTK HD zentral (HD01)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2026

---

Database coverage:
; ; Allianz-Lizenz ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 20 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---